Cardiovascular Systems, Inc. (CSII)
(Delayed Data from NSDQ)
$39.49 USD
+1.98 (5.28%)
Updated May 3, 2019 04:00 PM ET
After-Market: $39.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$39.49 USD
+1.98 (5.28%)
Updated May 3, 2019 04:00 PM ET
After-Market: $39.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Cardiovascular Systems (CSII) Finishes ECLIPSE Trial Enrollment
by Zacks Equity Research
Cardiovascular Systems' (CSII) ECLIPSE clinical trial data is likely to help physicians form an optimal treatment plan for patients with severely calcified coronary arteries.
Why Is NuVasive (NUVA) Down 15.9% Since Last Earnings Report?
by Zacks Equity Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Medtronic (MDT) Down 6.1% Since Last Earnings Report?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardiovascular Systems (CSII) Ails From Soft Volume, Macro Woes
by Zacks Equity Research
Tough competition and consistent net loss continue to pose threats to Cardiovascular Systems (CSII).
Abbott (ABT) to Expand Vascular Device Line With New Buyout
by Zacks Equity Research
Abbott's (ABT) latest deal will help gain access to Cardiovascular System's leading atherectomy device to treat vascular disease.
Cardiovascular Systems (CSII) Q2 Earnings, Revenues Miss
by Zacks Equity Research
With the announcement of the merger agreement with Abbott, Cardiovascular Systems (CSII) refrains from providing any update on the 2023 guidance.
Cardiovascular Systems (CSII) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -33.33% and 2.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardiovascular Systems (CSII) Global Sales Up, Margin Woe Stays
by Zacks Equity Research
Cardiovascular Systems (CSII) international revenues are showing strong growth in each of the key markets, including Japan, Europe, Asia Pacific and Canada.
Cardiovascular Systems (CSII) Q1 Earnings Miss, Revenues Top
by Zacks Equity Research
The launch of the Scoreflex scoring balloon receives a positive response and generates over $1.7 million in sales during the first quarter for Cardiovascular Systems (CSII).
Cardiovascular Systems (CSII) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -12.50% and 0.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardiovascular Systems (CSII) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Cardiovascular Systems (CSII) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Cardiovascular Systems (CSII) Down 18.9% Since Last Earnings Report?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardiovascular Systems (CSII) Q4 Earnings, Revenues Miss Mark
by Zacks Equity Research
According to Cardiovascular Systems (CSII), strong sequential growth in each of its segments is due to procedure recovery, focused commercial strategies and the launch of products.
Zynex Inc. (ZYXI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 14.29% and 0.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of 12.50% and 1.25%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
QuidelOrtho (QDEL) Stock Jumps 3.9%: Will It Continue to Soar?
by Zacks Equity Research
QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Cardiovascular Systems (CSII) Up 0.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardiovascular Systems' (CSII) Q3 Earnings Top Estimates
by Zacks Equity Research
Cardiovascular Systems' (CSII) third-quarter revenues declined year over year due to lower Coronary and peripheral revenues.
Cardiovascular Systems (CSII) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 10.71% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardiovascular Systems (CSII) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Cardiovascular Systems (CSII) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical
by Zacks Equity Research
Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical have been included in this Analyst Blog.
3 Medical Product Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.
Here's Why You Should Hold on to Cardiovascular Systems (CSII)
by Zacks Equity Research
Investors are optimistic about Cardiovascular Systems' (CSII) robust international growth and upcoming launches.
Cardiovascular Systems' (CSII) Low Procedure Volume Dents Sales
by Zacks Equity Research
Cardiovascular Systems (CSII) notes that recovery from the Delta variant has been suppressed by the emergence of the highly contagious Omicron variant.
Cardiovascular Systems (CSII) Finances New DCB Development
by Zacks Equity Research
Per the terms of the deal, Cardiovascular Systems (CSII) is providing milestone-based financing to CVT for the development of coronary and peripheral DCBs.